Quantum BioPharma Ltd. (NASDAQ: QNTM) has received U.S. Food and Drug Administration approval of its Investigational New Drug application for Lucid-MS, allowing the company to proceed with Phase 2 clinical testing of its multiple sclerosis candidate. The FDA clearance marks a significant step for a drug that aims to treat MS through a mechanism distinct from most existing therapies.
The planned Phase 2 study will be randomized, double-blind, and placebo-controlled, evaluating Lucid-MS for efficacy, safety, and tolerability in patients with MS. Researchers will assess clinical symptoms and changes visible through brain imaging. Unlike many approved MS therapies that modulate or suppress the immune system, Lucid-MS is designed to protect nerve cells by inhibiting PAD2, an enzyme associated with myelin damage. This approach could offer a different therapeutic option for patients, particularly those who do not respond adequately to current treatments. The compound previously completed Phase 1 trials in healthy volunteers, where the company reported a favorable safety profile and good tolerability.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company describes Lucid-MS as a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. For investors seeking more detail, the full announcement is available at https://ibn.fm/g5EXE.
Beyond its MS program, Quantum invented UNBUZZD(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum retains ownership of 19.48% of UWI as of June 30, 2026, and the agreement includes royalty payments of 7% of sales from UNBUZZD(TM) until payments to Quantum total $250 million. After that threshold, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. More information about UWI is available at www.unbuzzd.com.
The FDA clearance matters because MS affects millions worldwide, and many patients cycle through therapies without achieving durable control of the disease. A treatment that targets myelin protection rather than immune suppression could complement or provide an alternative to existing options. The company’s latest news and updates relating to QNTM are available in its newsroom at https://ibn.fm/QNTM. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
